Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from NKGen Biotech ( (NKGN) ).
On January 30, 2026, NKGen Biotech, Inc. and its affiliate NKGen Operating Biotech, Inc. entered into a third amendment to an existing secured promissory note with AlpineBrook Capital GP I Limited, securing an additional $251,000 in funding. The amendment increases the note’s total principal to $26,758,106 and specifies that interest on this latest tranche, termed the Fourth Additional New Loan, began accruing from the funding date of January 30, 2026, further expanding the company’s available debt financing and potentially supporting its near-term liquidity needs.
More about NKGen Biotech
Average Trading Volume: 6,871
Technical Sentiment Signal: Sell
Current Market Cap: $7.84M
See more insights into NKGN stock on TipRanks’ Stock Analysis page.